Opiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography (PET) Study of Naloxone Nasal Spray
Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
Opiant Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update
 More News »